- Affirmative Recovery
- American Indian Law and Policy
- Antitrust and Trade Regulation
- Appellate Advocacy and Guidance
- Business Litigation
- Civil Rights and Police Misconduct
- Class Action Litigation
- Commercial/Project Finance and Real Estate
- Corporate Governance and Special Situations
- Corporate Restructuring and Bankruptcy
- Domestic and International Arbitration
- Health Care Litigation
- Insurance and Catastrophic Loss
- Intellectual Property and Technology Litigation
- Litigation Support Services
- Mass Tort Attorneys
- Medical Malpractice Attorneys
- Personal Injury Attorneys
- Telecommunications Litigation and Arbitration
- Wealth Planning, Administration, and Disputes
-
April 12, 2021Robins Kaplan Executives Recognized by Twin Cities Business
-
April 1, 2021Robert Bennett Named a Midwest Trailblazer
-
March 31, 2021Robins Kaplan Attorneys Earn 2021 Readers' Choice Awards from JD Supra
-
April 13, 20, and 27, 2021Conversations on Cross-Border IP Protection and Enforcement
-
April 28, 2021Creating the Audit Clause for Today’s Compliance Review
-
April 29, 2021International Intellectual Property: Challenges of Cross-Border Litigation
-
April 2, 2021Prepare For Minn. Privacy Law To Catch Up To Calif., Wash.
-
Spring 2021Fiduciary or Foe? Revisiting Meinhard v. Salmon
-
Spring 2021Shareholder Risks in Mergers and Acquisitions
-
April 13, 2021Financial Daily Dose 4.13.2021 | Top Story: Ant Group Agrees to Sweeping Overhaul to Appease Chinese Regulators
-
April 12, 2021Financial Daily Dose 4.12.2021 | Top Story: Chinese Regulators Hit Alibaba With $2.8B Antitrust Fine
-
April 9, 2021Financial Daily Dose 4.9.2021 | Top Story: CV Amazon Leading in Early Alabama Warehouse Union-Vote Tally
IP: Generic Manufacturers Win In The Supreme Court
The Supreme Court overruled the Federal Circuit, ruling that generic manufacturers can use counterclaims to force corrections of patent use codes.
July 17, 2012
This spring the Supreme Court seems to have made it easier for generic drug manufacturers to contest the reach of patent protection for brand name drugs. In Caraco Pharmaceutical Labs, Ltd. v. Novo Nordisk, the Supreme Court ruled that a congressionally-created counterclaim allows generic manufacturers to challenge the exact uses a drug patent covers. Generic manufacturers can use the counterclaim in cases where a patent holder asserts infringement in response to an application to manufacture a generic version of a brand-name drug (i.e., Abbreviated New Drug Application or ANDA).
The articles on our website include some of the publications and papers authored by our attorneys, both before and after they joined our firm. The content of these articles should not be taken as legal advice. The views and opinions expressed in this article are those of the author(s) and do not necessarily reflect the views or official position of Robins Kaplan LLP.
Related Professionals
Bryan J. Vogel
Partner
Related Publications
Related News
If you are interested in having us represent you, you should call us so we can determine whether the matter is one for which we are willing or able to accept professional responsibility. We will not make this determination by e-mail communication. The telephone numbers and addresses for our offices are listed on this page. We reserve the right to decline any representation. We may be required to decline representation if it would create a conflict of interest with our other clients.
By accepting these terms, you are confirming that you have read and understood this important notice.